quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:28·17d
SECFiling
Alnylam Pharmaceuticals Inc. logo

SEC Form DEF 14A filed by Alnylam Pharmaceuticals Inc.

ALNY· Alnylam Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ALNY
    Alnylam Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies$330.00
  • Jan 28UpdateBarclays$527.00
  • Jan 7UpdateOppenheimer$500.00
  • Aug 4UpdateWolfe Research-
  • Aug 4UpdateOppenheimer$490.00
  • Jul 30UpdateRaymond James$370.00

Related

  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • PR7d
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
  • INSIDER16d
    SEC Form 4 filed by Mclaughlin Melissa
  • INSIDER16d
    SEC Form 3 filed by new insider Mclaughlin Melissa
  • SEC17d
    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.
  • PR24d
    New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.
  • PR30d
    Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022